| Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification tools D Lascano, JS Pak, M Kates, JB Finkelstein, M Silva, E Hagen, ... Urologic Oncology: Seminars and Original Investigations 33 (10), 426. e1-426 …, 2015 | 110 | 2015 |
| Delay from biopsy to radical prostatectomy influences the rate of adverse pathologic outcomes WT Berg, MR Danzig, JS Pak, R Korets, A RoyChoudhury, G Hruby, ... The Prostate 75 (10), 1085-1091, 2015 | 47 | 2015 |
| Prediagnostic serum levels of inflammatory biomarkers are correlated with future development of lung and esophageal cancer BR Keeley, F Islami, A Pourshams, H Poustchi, JS Pak, P Brennan, ... Cancer science 105 (9), 1205-1211, 2014 | 31 | 2014 |
| A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing … GJ DeCastro, W Sui, JS Pak, SM Lee, D Holder, MM Kates, RK Virk, ... The Journal of urology 204 (2), 247-253, 2020 | 28 | 2020 |
| Patterns of care for readmission after radical cystectomy in New York State and the effect of care fragmentation JS Pak, D Lascano, DH Kabat, JB Finkelstein, A RoyChoudhury, ... Urologic Oncology: Seminars and Original Investigations 33 (10), 426. e13 …, 2015 | 27 | 2015 |
| Utilization trends and outcomes up to 3 months of open, laparoscopic, and robotic partial nephrectomy JS Pak, JJ Lee, K Bilal, M Finkelstein, MA Palese Journal of Robotic Surgery 11 (2), 223-229, 2017 | 24 | 2017 |
| Utilization trends and short-term outcomes of robotic versus open radical cystectomy for bladder cancer JS Pak, JJ Lee, K Bilal, M Finkelstein, MA Palese Urology 103, 117-123, 2017 | 23 | 2017 |
| Gender Differences in the Urology Residency Match—Does It Make a Difference? CM Aisen, W Sui, JS Pak, M Pagano, KL Cooper, GM Badalato Urology 111, 39-43, 2018 | 21 | 2018 |
| A phase I trial for the use of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) in the treatment of BCG-refractory nonmuscle invasive urothelial carcinoma of the bladder. GJ DeCastro, W Sui, JS Pak, CT Abate-Shen, SM Lee, CB Anderson, ... Journal of Clinical Oncology 35 (6_suppl), 313-313, 2017 | 16* | 2017 |
| Prevalence of research publication misrepresentation among urology residency applicants and its effect on match success JS Pak, MJ Pagano, KL Cooper, JM McKiernan, GM Badalato Urology 99, 5-9, 2017 | 16 | 2017 |
| Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer JS Pak, CR Haas, CB Anderson, GJ DeCastro, MC Benson, ... Urologic Oncology: Seminars and Original Investigations, 2021 | 15 | 2021 |
| Case series: deep brain stimulation in patients with FXTAS RJ Hagerman, JS Pak, M Ortigas, J Olichnew, R Frysinger, M Harrison Brain Disord Ther 1 (104), 2, 2012 | 13 | 2012 |
| Oncologic outcomes of definitive treatments for low-and intermediate-risk prostate cancer after a period of active surveillance MJ Whalen, JS Pak, D Lascano, D Ahlborn, JT Matulay, JM McKiernan, ... Clinical genitourinary cancer 16 (2), e425-e435, 2018 | 10 | 2018 |
| Male Urethral, Penile, and Incontinence Surgery: Is Resident Exposure Adequate? JS Pak, M Silva, CM Deibert, KL Cooper, GM Badalato Urology 86 (5), 868-872, 2015 | 7 | 2015 |
| Bladder preservation for patients with bladder paragangliomas: case series and review of the literature EY Wang, JS Pak, RK Virk, CB Anderson, KA Healy, JA Lee, MC Benson, ... Urology, 2020 | 5 | 2020 |
| The intravesical injection of highly purified botulinum toxin for the treatment of neurogenic detrusor overactivity D Asafu-Adjei, A Small, G McWilliams, G Galea, DE Chung, JS Pak Canadian Urological Association Journal 14 (10), E520, 2020 | 4 | 2020 |
| A Urology Department's Experience at the Epicenter of the COVID-19 Pandemic JS Pak, CI Sayegh, MB Smigelski, JM McKiernan, KL Cooper Urology 144, 4-8, 2020 | 4 | 2020 |
| MP43-14 A PHASE 1 TRIAL OF INTRAVESICAL CABAZITAXEL, GEMCITABINE, AND CISPLATIN (CGC) FOR THE TREATMENT OF NON-MUSCLE INVASIVE BCG UNRESPONSIVE UROTHELIAL CARCINOMA OF THE BLADDER GJ DeCastro*, C Anderson, J Pak, M Kates, B Buckley-Matura, W Sui, ... The Journal of Urology 201 (Supplement 4), e623-e623, 2019 | 4 | 2019 |
| A phase I/II multi-center study of intravesical nanoparticle albumin-bound rapamycin (ABI-009) in the treatment of BCG refractory non-muscle invasive bladder cancer. JM McKiernan, D Lascano, J Ahn, R Ghandour, JS Pak, A RoyChoudhury, ... Journal of Clinical Oncology 33 (15_suppl), TPS4576-TPS4576, 2015 | 4 | 2015 |
| Diagnostic yield of repeat evaluation for asymptomatic microscopic hematuria after negative initial workup JS Pak, EY Wang, K Lee, LA Pina, JM McKiernan, CB Anderson Urologic Oncology: Seminars and Original Investigations 39 (5), 300. e1-300. e6, 2021 | 2 | 2021 |
